H.C. Wainwright lowered the firm’s price target on Viracta Therapeutics to $10 from $33 and keeps a Buy rating on the shares. The analyst pushed back the launch of nana-val in EBV-positive lymphomas to 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VIRX:
- Viracta Therapeutics’ NAVAL-1 trial reached efficacy threshold for expansion
- Viracta Therapeutics to Present at the Jefferies Healthcare Conference
- 2 “Strong Buy” Penny Stocks With Over 400% Upside on the Horizon
- Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates
- VIRX Earnings this Week: How Will it Perform?
